Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Hampp

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 9, 2008
Cost-utility analysis of rimonabant in the treatment of obesityChristian Hampp, Abraham G Hartzema, Teresa L Kauf
Journal of Intensive Care Medicine|January 25, 2011
Review of a large clinical series: once- versus twice-daily enoxaparin for venous thromboembolism prophylaxis in high-risk trauma patientsSarah Bush, Aimée LeClaire, Christian Hampp, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 24, 2010
Small budget impact is a result of flawed assumptions and ignores questionable cost-effectiveness for RSV prophylaxisChristian Hampp, Teresa L Kauf, Almut G Winterstein
Pharmacoepidemiology and Drug Safety|April 17, 2012
An algorithm to identify preterm infants in administrative claims dataEfe Eworuke, Christian Hampp, Arwa Saidi, et al.
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|November 3, 2012
Feasibility of short-term infusion of magnesium sulfate in pediatric patients with status asthmaticusJose Irazuzta, Tosha Egelund, Sarah K Wassil, et al.
JAMA Pediatrics|October 16, 2013
Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort studyAlmut G Winterstein, Caitlin A Knox, Paul Kubilis, et al.
Diabetes Care|March 14, 2014
Use of antidiabetic drugs in the U.S., 2003-2012Christian Hampp, Vicky Borders-Hemphill, David G Moeny, et al.
Archives of Pediatrics & Adolescent Medicine|February 9, 2011
Cost-effectiveness of respiratory syncytial virus prophylaxis in various indicationsChristian Hampp, Teresa L Kauf, Arwa S Saidi, et al.
Archives of Pediatrics & Adolescent Medicine|June 12, 2013
Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaid-ReplyChristian Hampp, Teresa L Kauf, Arwa S Saidi, et al.
European Journal of Pediatrics|August 8, 2021
Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics GuidelinesYoonyoung Choi, H Cody Meissner, Christian Hampp, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 9, 2008
Cost-utility analysis of rimonabant in the treatment of obesityChristian Hampp, Abraham G Hartzema, Teresa L Kauf
Journal of Intensive Care Medicine|January 25, 2011
Review of a large clinical series: once- versus twice-daily enoxaparin for venous thromboembolism prophylaxis in high-risk trauma patientsSarah Bush, Aimée LeClaire, Christian Hampp, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 24, 2010
Small budget impact is a result of flawed assumptions and ignores questionable cost-effectiveness for RSV prophylaxisChristian Hampp, Teresa L Kauf, Almut G Winterstein
Pharmacoepidemiology and Drug Safety|April 17, 2012
An algorithm to identify preterm infants in administrative claims dataEfe Eworuke, Christian Hampp, Arwa Saidi, et al.
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|November 3, 2012
Feasibility of short-term infusion of magnesium sulfate in pediatric patients with status asthmaticusJose Irazuzta, Tosha Egelund, Sarah K Wassil, et al.
JAMA Pediatrics|October 16, 2013
Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort studyAlmut G Winterstein, Caitlin A Knox, Paul Kubilis, et al.
Diabetes Care|March 14, 2014
Use of antidiabetic drugs in the U.S., 2003-2012Christian Hampp, Vicky Borders-Hemphill, David G Moeny, et al.
Archives of Pediatrics & Adolescent Medicine|February 9, 2011
Cost-effectiveness of respiratory syncytial virus prophylaxis in various indicationsChristian Hampp, Teresa L Kauf, Arwa S Saidi, et al.
Archives of Pediatrics & Adolescent Medicine|June 12, 2013
Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaid-ReplyChristian Hampp, Teresa L Kauf, Arwa S Saidi, et al.
European Journal of Pediatrics|August 8, 2021
Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics GuidelinesYoonyoung Choi, H Cody Meissner, Christian Hampp, et al.
Pageof 6